ReviewCurrent osteoporosis reports2004
Postmenopausal osteoporosis.
Review in Current osteoporosis reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Role and Validation of Lactylation-Related Gene Markers in Postmenopausal Osteoporosis.Applied biochemistry and biotechnology · 2025Article
- MiR-218-5p-dependent SOCS3 downregulation increases osteoblast differentiation inpostmenopausal osteoporosis.Journal of orthopaedic surgery and research · 2023Article
- Decoding the mechanism of Eleutheroside E in treating osteoporosis via network pharmacological analysis and molecular docking of osteoclast-related genes and gut microbiota.Frontiers in endocrinology · 2023Article
- Silencing Proteasome 26S Subunit ATPase 2 (PSMC2) Protects the Osteogenic Differentiation In Vitro and Osteogenesis In Vivo.Calcified tissue international · 2021Article
- Analysis and Validation of Hub Genes in Blood Monocytes of Postmenopausal Osteoporosis Patients.Frontiers in endocrinology · 2021Article
- Mesenchymal progenitors in osteopenias of diverse pathologies: differential characteristics in the common shift from osteoblastogenesis to adipogenesis.Scientific reports · 2016Article
- Management of age-related osteoporosis and prevention of associated fractures.Therapeutics and clinical risk management · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The postmenopausal state is the most common underlying cause for osteoporosis and most of our understanding of the condition relates to this group. Recent evidence has suggested that hormone therapy may no longer have the pre-eminent place it once held but the same studies have also confirmed its antifracture efficacy. However, an increasing variety of alternative therapies are available for the postmenopausal woman. Furthermore, recent understanding of the mechanisms of bone loss after estrogen withdrawal, suggest that newer even better targeted therapies might be developed in the future.
Indexed as
Identifiers
16036090What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.